Loyal Secures $22 Million to Advance Canine Longevity Drug Development

Loyal, a clinical-stage animal health company developing longevity drugs for dogs, has reached a significant regulatory milestone while securing $22 million in Series B-2 funding. The investment, led by Valor Equity Partners and Collaborative Fund, brings Loyal’s total funding to over $150 million.